Trivedi Amar, Knight Bradley P
Division of Cardiology, Department of Medicine, Northwestern University, Chicago, IL, USA.
Arrhythm Electrophysiol Rev. 2016;5(3):188-196. doi: 10.15420/aer.2016:30:2.
Hypertrophic cardiomyopathy (HCM) is a common and heterogeneous disorder that increases an individual's risk of sudden cardiac death (SCD). This review article discusses the relevant factors that are involved in the challenge of preventing SCD in patients with HCM. The epidemiology of SCD in patients is reviewed as well as the structural and genetic basis behind ventricular arrhythmias in HCM. The primary prevention of SCD with implantable cardioverter-defibrillator (ICD) therapy is the cornerstone of modern treatment for individuals at high risk of SCD. The focus here is on the current and emerging predictors of SCD as well as risk stratification recommendations from both North American and European guidelines. Issues related to ICD implantation, such as programming, complications and inappropriate therapies, are discussed. The emerging role of the fully subcutaneous ICD and the data regarding its implantation are reviewed.
肥厚型心肌病（HCM）是一种常见的异质性疾病，会增加个体心源性猝死（SCD）的风险。这篇综述文章讨论了在预防HCM患者发生SCD这一挑战中涉及的相关因素。回顾了患者SCD的流行病学以及HCM中心室心律失常背后的结构和遗传基础。植入式心律转复除颤器（ICD）治疗对SCD的一级预防是现代治疗高危SCD个体的基石。这里的重点是SCD的当前和新出现的预测因素以及北美和欧洲指南中的风险分层建议。讨论了与ICD植入相关的问题，如程控、并发症和不适当治疗。综述了完全皮下ICD的新作用及其植入数据。
